Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation and Genomic Instability in Prostate Cancer Statement of Translational Relevance

Conflict of interest statement: The authors do not declare any conflicts of interest. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. There is an urgent need for predictive progression markers to discriminate between aggressive and non-aggressive prostate cancers. By immunohistochemistry on a tissue microarray containing 12,427 prostate cancers, the authors demonstrate that strong cytoplasmic p62 staining was tightly linked to high Gleason grade, advanced pathological tumor stage, positive nodal status, positive resection margin, and early PSA recurrence. Analysis of cytoplasmic accumulation of p62 is a strong predictor of an adverse prognostic behavior of prostate cancer. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Purpose: Sequestosome 1 (p62) is a multifunctional adapter protein accumulating in autophagy-defective cells. Experimental Design: To evaluate the clinical impact and relationship with key genomic alterations in prostate cancer, p62 protein levels were analyzed by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Data on ERG status and deletions of PTEN, 3p13, 5q21 and 6q15 were available from earlier studies. Results: p62 immunostaining was absent in benign prostatic glands but present in 73% of 7,822 interpretable prostate cancers. Strong cytoplasmic p62 staining was tightly linked to high Gleason grade, advanced pathological tumor stage, positive nodal status, positive resection margin, and early PSA recurrence (p<0.0001 each). Increased levels of p62 were significantly linked to TMPRSS2-ERG fusions, both by FISH and immunohistochemical analysis (p<0.0001 each). For example, moderate or strong p62 immunostaining was seen in 28.5% of cancers with TMPRSS2:ERG fusion detected by FISH and in 23.1% of cancers without such rearrangements (p<0.0001). Strong p62 staining was significantly linked to presence of all tested deletions, including PTEN (p<0.0001), 6q15 (p<0.0001), 5q21 (p=0.0002), and 3p13 (p=0.0088), 6q15 (p<0.0001), suggesting a link between p62 accumulation and loss of genomic stability. The prognostic role of p62 protein accumulation was striking and independent of Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA, irrespective of whether preoperative or postoperative parameters were used for modeling. Conclusions: Our study identifies cytoplasmic accumulation of p62 as a strong predictor of an adverse prognostic behavior of prostate cancer independently from established clinico-pathological findings. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

[1]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  G. Sauter,et al.  The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG‐negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression , 2014, International journal of cancer.

[3]  Christian M. Metallo,et al.  Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. , 2014, Cancer cell.

[4]  A. Partin,et al.  Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis. , 2013, The Journal of urology.

[5]  G. Sauter,et al.  High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers , 2013, Molecular oncology.

[6]  G. Sauter,et al.  High mitochondria content is associated with prostate cancer disease progression , 2013, Molecular Cancer.

[7]  H. Okabe,et al.  Association of p62/SQSTM1 Excess and Oral Carcinogenesis , 2013, PloS one.

[8]  N. Yoo,et al.  Alteration of p62/SQSTM1 Expression Is Uncommon in Gastrointestinal and Prostate Cancer Tissues , 2013, Gut and liver.

[9]  S. Kurtz,et al.  Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.

[10]  Jia Fu,et al.  Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer , 2013, OncoTargets and therapy.

[11]  D. Klionsky,et al.  Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability. , 2013, Cancer research.

[12]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[13]  Jun Yu,et al.  FK-16 Derived from the Anticancer Peptide LL-37 Induces Caspase-Independent Apoptosis and Autophagic Cell Death in Colon Cancer Cells , 2013, PloS one.

[14]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[15]  W. Ding,et al.  Role of p62/SQSTM1 in liver physiology and pathogenesis , 2013, Experimental biology and medicine.

[16]  G. Sauter,et al.  Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers , 2013, Journal of Clinical Pathology.

[17]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[18]  A. McEvoy,et al.  The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells , 2013, Oncogene.

[19]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[20]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[21]  I. Thompson,et al.  Prostate cancer--uncertainty and a way forward. , 2012, The New England journal of medicine.

[22]  H. Kubo,et al.  Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma , 2012, Cancer science.

[23]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[24]  Keiji Tanaka,et al.  Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells , 2011, The Journal of cell biology.

[25]  Y. Eishi,et al.  Autophagy-deficient mice develop multiple liver tumors. , 2011, Genes & development.

[26]  G. Bhanot,et al.  Autophagy Suppresses Tumorigenesis through Elimination of p62 , 2011, Cell.

[27]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[28]  C. Cooper,et al.  ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.

[29]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[30]  J. Flores,et al.  The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.

[31]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[32]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[33]  N. Sato,et al.  Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue , 2006, Histopathology.

[34]  M. Glotzer,et al.  Cytokinesis: welcome to the Rho zone. , 2005, Trends in cell biology.

[35]  G. Bjørkøy,et al.  p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death , 2005, The Journal of cell biology.

[36]  B. Wold,et al.  p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells , 2003, Oncogene.

[37]  Y. Lee,et al.  Immediate early response of the p62 gene encoding a non‐proteasomal multiubiquitin chain binding protein , 1998, FEBS letters.

[38]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[39]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[40]  G. Sauter,et al.  High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy , 2014, Modern Pathology.

[41]  P. Auberger,et al.  When autophagy meets cancer through p62/SQSTM1. , 2012, American journal of cancer research.